New Ultrafiltration Cassettes from Pall Enhance High Performance Bioprocessing

Biopharmaceutical manufacturers require efficient, high-throughput ultrafiltration technologies to handle higher protein concentrations. To address this need, Pall Corporation (NYSE:PLL) introduces the new Omega^TM T- Series Membrane Cassettes to offer enhanced processing efficiencies and greater product recovery. The new cassettes are constructed with high-performance materials that reduce extractables to deliver high-purity biological solutions. These cassettes assure effective mass transfer of proteins, which is critical for biotech manufacturers given the significant cost of even minimal volumes of purified protein solutions used in downstream drug production. Pall also introduces single-use Minimate^TM II encapsulated membrane cassettes, the latest addition to the company's line of single-use technologies.

 

The Omega T-Series cassettes incorporate Pall's high-yield Omega membranes and a new polypropylene screen to increase processing flux rates and product recovery. Materials of construction chosen for the Omega T-Series cassettes ensure a low level of extractables. This reduces the amount of rinsing volumes that are required prior to cassette use, saving time and material costs.

The cassettes feature a new exterior design with deeper notches so that cassettes fit more snugly and securely in the holders. The more rigid encapsulation material reduces over-torquing issues that compress membrane channels and impede product flow, which might occur with traditional manual cassette holders.

 

"Our versatile ultrafiltration technologies create value for our customers, especially those faced with the challenge of efficiently purifying recombinant proteins or monoclonal antibodies," says Thomas Scholz, Marketing Director, TFF Technologies, Pall Life Sciences.

"The new Omega T-Series and Minimate II cassettes strengthen our ultrafiltration portfolio and help customers optimize processing performance."

 

The Omega T-Series cassettes are available in fully scalable formats to facilitate their use in a wide variety of bioprocessing applications. Offered in four sizes, 200 cm², 0.1 m², 0.5 m², and 2.5 m², the cassettes integrate well with most standard stainless steel holders.

For added ultrafiltration versatility, Pall also offers the two smaller sizes of the Omega
T-Series cassettes in the Minimate II single-use format module. Minimate II cassettes are ideal for trials and pilot experiments and can easily scale with Omega T-Series cassettes as they comprise identical materials of construction and flow paths to ensure true linearity in operations. This allows manufacturers to gain critical time-to-market advantages through accelerated scale-up and reduction in the number of trials before full production. Minimate ll cassettes do not require torquing, and as single-use units, these cassettes are easy to use and install, resulting in additional efficiency benefits.  

 

About Pall Corporation

Pall Corporation is the global leader in the rapidly growing field of filtration, separation and purification. Pall is organized into two businesses: Life Sciences and Industrial. These businesses provide leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, energy, electronics, municipal and industrial water purification, aerospace, transportation and broad industrial markets. Total revenues for fiscal year 2006 were $2.0 billion. The Company headquarters is in East Hills, New York with extensive operations throughout the world. For more information visit Pall at www.pall.com.